ABSTRACT
INTRODUCTION: Clinical observations and laboratory data indicate that patients with myeloproliferative syndrome (MPS) have hemostasis disorders that manifest with haemorrhagic diathesis or thrombotic disease. The role of fibrinolytic system is not clear in the pathomechanism of the disorders. In the study we aimed to evaluate fibrinolysis system in blood plasma of the patients with selected myeloproliferative syndromes on the basis of examinations of plasminogen activators (tissue--t-PA and urokinase-type--u-PA) and type 1 and type 2 plasminogen activator inhibitors (PAI-1 and PAI-2). MATERIAL AND METHODS: Forty-two patients (F/M 28/14) aged 36-78 years (average age--54 years) were enrolled into the study. Among the patients were 20 individuals with chronic myeloid leukaemia (CML), 17 with essential thrombocytemia (ET) and 5 with myelofibrosis (MF) treated in Provincial Haematological Outpatient Clinic in Bydgoszcz. Forty healthy volunteers (F/M 30/10) aged 24-65 (average 53) were included in control group. In citrate venous blood, the following parameters were determined: concentrations of antigen t-PA, u-PA, PAI-1, PAI-2, concentration of plasmin-alpha-2-antiplasmin complexes (PAP) determined with the use of ELISA technique, PAI-1 activity with amidolytic method, euglobulin lysis time (ELT) according to Kowarzyk-Buluk and fibrinogen/fibrin degradation products (FDP) concentration with the use of Merskey's method. RESULTS: Performed evaluations show that besides normal ELT elevated concentrations of FDP and PAP complexes occur in the blood of patients with myeloproliferative syndromes (MPS.). In studied myeloproliferative syndromes, high concentration of PAI-1 Ag and very low activity of PAI-1 were observed. In the patients with MPS intensified plasminogenesis and increased fibrin degradation were demonstrated. The role of granulocyte elastase is considered in activation of fibrinolysis system.
Subject(s)
Myeloproliferative Disorders/blood , Plasminogen Activator Inhibitor 1/blood , Plasminogen Activator Inhibitor 2/blood , Tissue Plasminogen Activator/blood , Urokinase-Type Plasminogen Activator/blood , Adult , Aged , Case-Control Studies , Female , Fibrinolysis , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood , Male , Middle Aged , Primary Myelofibrosis/blood , Thrombocythemia, Essential/bloodABSTRACT
The aim of study was to evaluate the influence of the treatment with oxygen-ozone mixture on the blood plasma antigen concentration of tissue plasminogen activator (t-PA) and von Willebrand factor (vWF) in patients suffering from atherosclerotic disease of lower extremities. The study was performed in the group of 28 (M/F 22/6) patients means aged 64.1 years with atherosclerotic diseases of lower extremities, in whom 2 weeks therapy with oxygen-ozone mixture was used. The control group consisted of 30 healthy volunteers in mean age 51.0 years. In the blood plasma obtained from the patients before and after treatment with oxygen-ozone mixture and from the control group determinations of t-PA and vWF antigen using ELISA were done. Both parameters were significantly increased in the patients before the treatment in comparison to the healthy controls. The treatment with oxygen-ozone therapy caused in patients slight statistically not significant raise of t-PA and vWF antigen showing the endothelial stimulation but not the destruction of vascular endothelium.
Subject(s)
Arteriosclerosis/pathology , Arteriosclerosis/therapy , Leg/pathology , Ozone/therapeutic use , Adult , Aged , Aged, 80 and over , Antigens/blood , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiology , Female , Humans , Male , Middle Aged , Oxygen/pharmacology , Oxygen/therapeutic use , Ozone/pharmacology , Peripheral Vascular Diseases/pathology , Tissue Plasminogen Activator/blood , Tissue Plasminogen Activator/drug effects , von Willebrand FactorABSTRACT
The aim of the study was to evaluate function of endothelial cells in the patients with hyperthyrosis before thyrostatic treatment on the base of known markers of endothelial disturbances: von Willebrand factor and tissue plasminogen activator. The study was performed in the 36 patients aged 20-60 (means 36.7) years suffering from Graves disease and in 17 patients with hyperthyrotic goitre aged 30-59 (means 45.8). The control group consisted of 40 healthy volunteers. In the blood plasma concentration of tissue plasminogen activator (t-PA) and von Willebrand factor (vWF) antigen were determined with enzyme-linked immunoassay (ELISA). In patients with hyperthyroidism significantly increased antigen concentration of both studied parameters were observed. It seems that increased concentration of t-PA and vWF antigen in the blood of hyperthyrotic patients was the result of the release of them from injured thyroid gland by disease or of stimulating effect of thyroid hormones on the t-PA and vWF synthesis in the endothelial cells.
Subject(s)
Endothelium/cytology , Endothelium/physiology , Hyperthyroidism/blood , Tissue Plasminogen Activator/physiology , von Willebrand Factor/physiology , Adult , Biomarkers , Female , Humans , Male , Middle AgedABSTRACT
Twenty patients with recently recognised bronchial asthma and 22 age and sex-matched healthy control subjects were studied. In both groups the activated partial thromboplastin time (APTT), prothrombin ratio (INR), fibrinogen, euglobulin lysis time (ELT), platelet number and platelet adhesion and aggregation, tissue plasminogen activator antigen (t-PA Ag) and activity of plasminogen activator inhibitor (PAI-1) were tested and compared. Statistically significant differences between asthmatic and control groups concerning adhesion, aggregation, APTT and ELT were found. In asthmatic group after 14 days of prednisone administration in a dose of 20 mg/d statistically significant (p < 0.05) shortening of APTT, and a significant increase of adhesion, aggregation and PAI-1 activity were found. These results suggest that in asthmatic patients after prednisone treatment platelet activity appeared in a form of intensification of adhesion and of aggregation degree, also the activity of PAI-1 probably of the platelet origin increased.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Asthma/blood , Asthma/drug therapy , Blood Platelets/drug effects , Plasminogen Inactivators/metabolism , Prednisone/pharmacology , Adult , Anti-Inflammatory Agents/therapeutic use , Female , Humans , Male , Middle Aged , Partial Thromboplastin Time , Platelet Aggregation/drug effects , Platelet Count/drug effects , Prednisone/therapeutic useABSTRACT
The activity of alpha 2-macroglobulin in the blood of the patients with prostatic carcinoma (PC) and benign prostatic hyperplasia (BPH) was examined. It was shown an decrease of alpha 2-macroglobulin in patients with prostatic carcinoma in comparison with control group consisted of the patients with benign prostatic hyperplasia. The low activity of alpha 2-macroglobulin in the blood od the patients with PC can be a symptom of an increase risk of haemorrhagic complications.
Subject(s)
Carcinoma/blood , Prostatic Neoplasms/blood , alpha-Macroglobulins/physiology , Aged , Aged, 80 and over , Humans , Male , Middle AgedABSTRACT
The activity of Protein C in the blood of the patients with prostatic carcinoma and benign prostatic hyperplasia was examined. It was observed a slightly decrease of activity of protein C in the blood the patients with prostatic carcinoma. The observation of the activity of Protein C is useful because it allow to differentiate from patients with prostatic carcinoma a group of high risk of haemorrhagic complications. The activity of Protein C may be a prognostic factor of a progress of a prostatic carcinoma.
